文献速递临床试验与 GCP基础与转化研究

利伐沙班对比无治疗用于ER阴性I-III期早期乳腺癌(TIP试验):术前II期机会窗随机对照试验方案

Rivaroxaban compared to no treatment in ER-negative stage I-III early breast cancer patients (the TIP Trial): study protocol for a phase II preoperative window-of-opportunity study design randomised controlled trial.
PubMed 文献 · Trials · 2020-08-27

乳腺癌患者静脉血栓栓塞风险增加,临床前模型显示抗凝药可抑制肿瘤生长。本研究为英国术前机会窗II期随机对照试验,计划入组88例初治早期乳腺癌患者,随机接受利伐沙班20 mg每日一次治疗11-17天或不治疗,主要终点为肿瘤Ki67变化,旨在评估利伐沙班在ER阴性早期乳腺癌中的抗增殖及其他抗癌进展机制。

要点

  • 利伐沙班20 mg每日一次术前治疗11-17天,主要终点为肿瘤Ki67变化。
  • 纳入88例初治ER阴性早期乳腺癌患者,随机对照设计。
  • 首次在早期乳腺癌中探索抗凝药的抗癌作用。

核心结论

  • 本试验将评估利伐沙班在ER阴性早期乳腺癌患者中的抗增殖及其他抗癌进展机制,为抗凝药抗癌作用提供早期临床证据。

研究设计与样本

  • 英国术前机会窗II期随机对照试验,计划随机88例初治早期乳腺癌患者。
  • 干预为利伐沙班20 mg每日一次治疗11至17天,对照为不治疗。
  • 治疗在手术或重复空芯针活检前24小时(范围18-36小时)停止,术后或活检后随访2周。

关键数值与推荐

  • 主要终点为肿瘤Ki67变化。
  • 次要终点包括肿瘤凋亡与血管生成标志物、外源性凝血通路激活、转移全身标志物、肿瘤负荷和凝血标志物。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Breast cancer patients are at a four-fold increased risk of developing a venous thromboembolism (VTE), a major cause of death in this group. Conversely, coagulation factors promote tumour growth and metastasis. This has been evidenced in preclinical models, with an inhibitory effect of anticoagulants on cancer growth through proliferative, angiogenic, apoptotic, cancer stem cell and metastatic processes. The extrinsic clotting pathway is also more upregulated in patients in the relatively poorer prognosis oestrogen receptor (ER)-negative breast cancer subgroup, with increased tumour stromal expression of the coagulation factors Tissue Factor and thrombin. Rivaroxaban (Xarelto®, Bayer AG, Leverkusen, Germany) is a direct oral anticoagulant (DOAC). It is a Factor Xa inhibitor that is routinely prescribed for the prevention of stroke in non-valvular atrial fibrillation and for both VTE prophylaxis and treatment. This trial will assess the anti-proliferative and other anti-cancer progression mechanisms of Rivaroxaban in ER-negative early breast cancer patients. METHODS: This UK-based preoperative window-of-opportunity phase II randomised control trial will randomise 88 treatment-naïve early breast cancer patients to receive 20 mg OD Rivaroxaban treatment for 11 to 17 days or no treatment. Treatment will be stopped 24 h (range 18-36 h) prior to surgery or repeat core biopsy. All patients will be followed up for 2 weeks following surgery or repeat core biopsy. The primary endpoint is change in tumour Ki67. Secondary outcome measures include tumour markers of apoptosis and angiogenesis, extrinsic clotting pathway activation and systemic markers of metastasis, tumour load and coagulation. DISCUSSION: Laboratory evidence supports an anti-cancer role for anticoagulants; however, this has failed to translate into survival benefit when trialled in patients with metastatic disease or poor prognosis cancers, such as lung cancer. Subgroup analysis supported a potential survival benefit in better prognosis advanced disease patients. This is the first study to investigate the anti-cancer effects of anticoagulants in early breast cancer. TRIAL REGISTRATION: UK National Research Ethics Service (NRES) approval 15/NW/0406, MHRA Clinical Trials Authorisation 48380/0003/001-0001. The sponsor is Manchester University NHS Foundation Trust, and the trial is co-ordinated by Cancer Research UK Liverpool Cancer Trials Unit (LCTU). EudraCT 2014-004909-33 , registered 27 July 2015. ISRCTN14785273 .

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Castle J, Blower E, Bundred NJ, et al. Rivaroxaban compared to no treatment in ER-negative stage I-III early breast cancer patients (the TIP Trial): study protocol for a phase II preoperative window-of-opportunity study design randomised controlled trial. Trials. 2020. PMID: 32854772. doi:10.1186/s13063-020-04675-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。